1,3,5-Tri-O-benzoyl-D-Ribofuranose CAS 22224-41-5 Purity ≥99.0% Clofarabine Intermediate High Purity

1,3,5-Tri-O-benzoyl-D-Ribofuranose (CAS: 22224-41-5) is a starting material for nucleoside synthesis. It can be used as an intermediate of Clofarabine (CAS: 123318-82-1). Clofarabine is a novel purine nucleoside anticancer drugs is first successfully developed by the Top10 biopharmaceutical company of the United States-Genzyme Corporation with the trade names being “Clofarabine”. On December 28, 2004 the FDA used fast-track for approval of Clofarabine for application to children with refractory or relapsed acute lymphocytic leukemia. Clofarabine combines the advantages of Fludarabine and Cladribine to inhibit both DNA polymerase and RIbonucleic acid reductase. It is currently the only drug suitable for the treatment of childhood leukemia. Studies have proved that its therapeutic efficiency is very high, and the total response rate of patients with no response to two conventional chemotherapy is 31%. And patient tolerance is good, no unpredictable adverse reactions;  It has potentially broad-spectrum antitumor properties.